Beyond BMI: The need for new guidelines governing the use of bariatric and metabolic surgery

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 2, 2014, Pages 175-181

  Cummings, David E ^a   Cohen, Ricardo V ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Hospital Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BARIATRIC SURGERY; BODY MASS; DIABETES MELLITUS, TYPE 2; OBESITY; PRACTICE GUIDELINE; TRENDS;

BARIATRIC SURGERY; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; GUIDELINES AS TOPIC; OBESITY;

EID: 84893348800     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70198-0     Document Type: Review

References (76)

1. NIH conference. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991, 115:956-961. Consensus Development Conference Panel.
2. Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009, 361:445-454. the Longitudinal Assessment of Bariatric Surgery (LABS) Consortium.
3. Nguyen NT, Hinojosa M, Fayad C, Varela E, Wilson SE Use and outcomes of laparoscopic versus open gastric bypass at academic medical centers. J Am Coll Surg 2007, 205:248-255.
4. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995, 222:339-350.
5. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003, 238:467-484.
6. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
7. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248. 56.e5.
8. Thaler JP, Cummings DE Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009, 150:2518-2525.
9. Bariatric surgery utilization and outcomes in 1998 and 2004. Statistical Brief #23 Agency for Healthcare Research and Quality (AHRQ), (accessed Jan 14, 2014). http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.pdf.
10. Encinosa WE, Bernard DM, Du D, Steiner CA Recent improvements in bariatric surgery outcomes. Med Care 2009, 47:531-535.
11. Higa K, Ho T, Tercero F, Yunus T, Boone KB Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg Obes Relat Dis 2011, 7:516-525.
12. Khuri SF, Najjar SF, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg 2001, 234:370-382. the VA National Surgical Quality Improvement Program.
13. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement US Department of Health and Human Services, National Institutes of HealthNational Institutes of Health, (accessed March 5, 2013). http://consensus.nih.gov/1991/1991gisurgeryobesity084html.htm.
14. Lechner GW, Elliott DW Comparison of weight loss after gastric exclusion and partitioning. Arch Surg 1983, 118:685-692.
15. Pories WJ, Flickinger EG, Meelheim D, Van Rij AM, Thomas FT The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion. Ann Surg 1982, 196:389-399.
16. Näslund I Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl 1987, 536:1-60.
17. Sugerman HJ, Starkey JV, Birkenhauer R A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg 1987, 205:613-624.
18. Hall JC, Watts JM, O'Brien PE, et al. Gastric surgery for morbid obesity. The Adelaide Study. Ann Surg 1990, 211:419-427.
19. MacLean LD, Rhode BM, Sampalis J, Forse RA Results of the surgical treatment of obesity. Am J Surg 1993, 165:155-160.
20. Lee WJ, Huang MT, Yu PJ, Wang W, Chen TC Laparoscopic vertical banded gastroplasty and laparoscopic gastric bypass: a comparison. Obes Surg 2004, 14:626-634.
21. Olbers T, Fagevik-Olsén M, Maleckas A, Lönroth H Randomized clinical trial of laparoscopic Roux-en-Y gastric bypass versus laparoscopic vertical banded gastroplasty for obesity. Br J Surg 2005, 92:557-562.
22. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693. the Swedish Obese Subjects Study Scientific Group.
23. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012, 367:695-704.
24. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012, 35:1420-1428.
25. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012, 308:1122-1131.
26. Eid GM, Brethauer S, Mattar SG, Titchner RL, Gourash W, Schauer PR Laparoscopic sleeve gastrectomy for super obese patients: forty-eight percent excess weight loss after 6 to 8 years with 93% follow-up. Ann Surg 2012, 256:262-265.
27. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012, 307:56-65.
28. Sjöström L, Gummesson A, Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009, 10:653-662. the Swedish Obese Subjects Study.
29. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752. the Swedish Obese Subjects Study.
30. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753-761.
31. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004, 240:416-423.
32. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154. The Look AHEAD Research Group.
33. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012, 366:1577-1585.
34. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366:1567-1576.
35. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323.
36. O'Brien PE, Sawyer SM, Laurie C, et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. JAMA 2010, 303:519-526.
37. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013, 309:2240-2249.
38. Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009, 13:1-190. 215-357, iii-iv.
39. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006, 243:108-114.
40. Rubino F, Kaplan LM, Schauer PR, Cummings DE The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010, 251:399-405. the Diabetes Surgery Summit Delegates.
41. Rubino F, Schauer PR, Kaplan LM, Cummings DE Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010, 61:393-411.
42. 2: an integrative review of early studies. Obes Surg 2010, 20:776-790.
43. 2. Surg Obes Relat Dis 2010, 6:332-338.
44. Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011, 146:143-148.
45. Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery 2010, 147:664-669.
46. 2. J Gastrointest Surg 2008, 12:945-952.
47. 2. Diabetologia 2009, 52:1027-1030.
48. Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg 2011, 253:699-703.
49. 2. J Obes 2012, 2012:147256.
50. Demaria EJ, Winegar DA, Pate VW, Hutcher NE, Ponce J, Pories WJ Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg 2010, 252:559-566.
51. 2: a literature review. Diabetes Technol Ther 2012, 14:365-372.
52. Dixon JB, Zimmet P, Alberti KG, Rubino F Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011, 28:628-642. the International Diabetes Federation Taskforce on Epidemiology and Prevention.
53. Zimmet P, Alberti KG, Rubino F, Dixon JB IDF's view of bariatric surgery in type 2 diabetes. Lancet 2011, 378:108-110.
54. Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011. Obes Surg 2012, 22:677-684.
55. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534. the Women's Health Initiative Investigators.
56. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
57. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
58. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. the Action to Control Cardiovascular Risk in Diabetes Study Group.
59. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. the ADVANCE Collaborative Group.
60. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. the VADT Investigators.
61. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
62. Gaede P, Lund-Andersen H, Parving HH, Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
63. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. the Diabetes Prevention Program Research Group.
64. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. the Diabetes Prevention Program Research Group.
65. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011, 34:1481-1486. the Look AHEAD Research Group.
66. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. the ADOPT Study Group.
67. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481. the LEAD-3 (Mono) Study Group.
68. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135. the RECORD Study Team.
69. Wulffelé MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002, 25:2133-2140.
70. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736-1747. the 4-T Study Group.
71. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013, 36:2175-2182.
72. Garrido-Sanchez L, Murri M, Rivas-Becerra J, et al. Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy. Surg Obes Relat Dis 2012, 8:145-150.
73. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013, 23:93-102.
74. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
75. Sjöström L Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med 2013, 273:219-234.
76. Bays HE, Chapman RH, Grandy S The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007, 61:737-747. the SHIELD Investigators' Group.